Durukan Dr. Emil, Kraglund Rune H, Rashid Dr. Shad A, Thorkilgaard Dr. Tine, Jensen Christian F S, Fode Prof. Mikkel

(332) THE EFFECT OF PDE5-INHIBITORS IN THE MANAGEMENT OF PEYRONIE’S DISEASE IN THE ACTIVE PHASE: A RETROSPECTIVE COHORT STUDY

  • Urology
  • Reproductive Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
Save to CiteDrive Show PDF

Abstract Objectives Experimental models and preliminary human trials have implied that continuous treatment with PDE-5 inhibitors may be a viable treatment of Peyronie’s disease (PD) in the active phase. The purpose of this study is to assess the effect of PDE-5 inhibitors on penile curvature in the management of PD in the active phase. Methods We performed a retrospective cohort study of patients with PD in the active phase seen between 2017 and 2021. Patients were included if they had at least two recorded visits with curvature measurements. Patient characteristics and PD characteristics including pain, treatment and, curvatures at each visit were registered. The primary outcome was the change in penile curvature between visits in patients receiving daily PDE-5 inhibitor compared to patients receiving no treatment. Results 135 patients were identified, with 102 (75.6%) receiving treatment with daily PDE-5 inhibitors and 33 (24.4%) receiving no treatment. The mean age in the treatment group and control group was 58 (±10.1) and 58.4 (±13.5) years, respectively. The mean time between the onset of symptoms and the first clinical visit was 11.3 (±8.6) months in the treatment group and 13.3 (±18.7) months in the control group. The mean change in penile curvature between the first and last observations in the treatment group and control group was 1.67° (±9.7) and -0.3° (±12.9), respectively (p = 0.9). A multivariate analysis controlling for baseline curvature and time from onset and the first visit showed no statistically significant differences in penile curvature changes (-0.28, 95% CI [-4.4, 3.8] p = 0.9). Conclusions Continuous PDE-5 inhibitor treatment appeared to have no influence on the progression of PD in the active phase. The main limitation of the study is its retrospective nature. This may have masked a potential effect as it can be speculated that patients with clinically significant improvements in curvature are less likely to show up for follow-up visits. Conflicts of Interest The authors declare no conflicts of interest.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive